Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.

Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Iozzo P

Hepatology (Baltimore, Md.)1 Dec 2016Cited by 83 (Europe PMC)

PMID27639082DOI10.1002/hep.28827PepBankPUB-27639082

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialMechanism
In male subjects undergoing an oral glucose tolerance test, exenatide reduced oral glucose absorption compared with placebo.
In plain wordsIn men during a glucose test, exenatide reduced glucose absorption compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOral glucose absorption
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908201
02HumanNon-randomized trialEfficacy outcome
In male subjects, exenatide reduced plasma glucose over 0 to 120 minutes after glucose ingestion compared with placebo.
In plain wordsIn men, exenatide reduced blood sugar after glucose ingestion compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma glucose during oral glucose tolerance test
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908202
03HumanNon-randomized trialMechanism
In male subjects, exenatide reduced insulin concentrations after glucose ingestion compared with placebo.
In plain wordsIn men, exenatide lowered insulin after glucose ingestion compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma insulin during oral glucose tolerance test
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneousAs given in this study (human).
Measurements
Insulin
23 mU/L
exenatide
Insulin
41 mU/L
placebo
Source sentences
Summary
EX decreased Hep-IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion.
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908203
04HumanNon-randomized trialEfficacy outcome
In male subjects undergoing a glucose tolerance test, exenatide decreased hepatic insulin resistance compared with placebo.
In plain wordsIn men during a glucose test, exenatide reduced liver insulin resistance compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHepatic insulin resistance
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Liver
Studied dose
5 μg · subcutaneousAs given in this study (human).
Measurements
Hepatic insulin resistance
197
placebo
Hepatic insulin resistance
130
exenatide
Source sentences
Summary
EX decreased Hep-IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908204
05HumanNon-randomized trialMechanism
In male subjects undergoing a glucose tolerance test, exenatide increased hepatic uptake of oral glucose compared with placebo.
In plain wordsIn men during a glucose test, exenatide increased liver glucose uptake compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHepatic glucose uptake
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Liver
Studied dose
5 μg · subcutaneousAs given in this study (human).
Measurements
Hepatic glucose uptake
23 [μmol/min/L]/[μmol/min/kg]
placebo
Hepatic glucose uptake
232 [μmol/min/L]/[μmol/min/kg]
exenatide
Source sentences
Summary
EX decreased Hep-IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908205
06HumanNon-randomized trialEfficacy outcome
In male subjects undergoing a glucose tolerance test, exenatide decreased adipose insulin resistance compared with placebo.
In plain wordsIn men during a glucose test, exenatide reduced fat tissue insulin resistance compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAdipose insulin resistance
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneousAs given in this study (human).
Measurements
Adipose insulin resistance
23
placebo
Adipose insulin resistance
13
exenatide
Source sentences
Summary
EX enhanced insulin suppression of RaGly by decreasing Adipo-IR (23 ± 4 to 13 ± 3; P = 0.009).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908206
07HumanNon-randomized trialMechanism
In male subjects undergoing a glucose tolerance test, exenatide enhanced insulin suppression of glycerol appearance compared with placebo.
In plain wordsIn men during a glucose test, exenatide strengthened insulin suppression of fat breakdown compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseInsulin suppression of lipolysis
Study
n = 15
Comparator
Placebo
Outcome group
Lipids · Metabolic and weight
Studied dose
5 μg · subcutaneousAs given in this study (human).
Source sentences
Summary
EX enhanced insulin suppression of RaGly by decreasing Adipo-IR (23 ± 4 to 13 ± 3; P = 0.009).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
Report a problemFND-2763908207

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

08HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialMechanism
In male subjects during glucose testing, insulin had no significant effect on adipose tissue glucose uptake under exenatide or placebo.
In plain wordsIn men during glucose testing, insulin had no significant effect on fat tissue glucose uptake under exenatide or placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdipose tissue glucose uptake
Study
n = 15
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Adipose glucose uptake
1.16 [μmol/min/L]/[μmol/min/kg]
exenatide
Adipose glucose uptake
1.36 [μmol/min/L]/[μmol/min/kg]
placebo
Source sentences
Summary
No significant effect of insulin was observed on ATGU (EX = 1.16 ± 0.15 vs. PLC = 1.36 ± 0.13 [μmol/min/L]/[μmol/min/kg]).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m² ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double-blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75-g oral glucose tolerance test (OGTT).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2763908208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01588418

Acute Effect of Exenatide on Brain Glucose Metabolism

The University of Texas Health Science Center at San Antonion = 15Jul 2010 to Jul 2015

Impaired Glucose Tolerance (IGT) · Diabetes

Trial page ClinicalTrials.govUpdated 24 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.